Zepbound vs Mounjaro: What's the Difference?
Zepbound and Mounjaro both contain tirzepatide — so what's the difference? This guide explains FDA approvals, doses, pricing, and which to choose for weight loss.
More on Tirzepatide Options
How Tirzepatide Works
The science behind tirzepatide's dual GIP/GLP-1 mechanism.
Tirzepatide Side Effects Management
How to manage the most common side effects.
Ozempic vs Mounjaro
Full brand-name comparison of the two leading GLP-1 drugs.
Best Weight Loss Medication 2026
Where tirzepatide ranks among all weight loss drugs.
Same Drug, Two Brand Names
The short answer to "what's the difference between Zepbound and Mounjaro?" is: the FDA indication and the branding. Both contain tirzepatide — a dual GIP and GLP-1 receptor agonist developed by Eli Lilly — at identical doses, with the same mechanism of action, the same clinical efficacy, and the same side effect profile.
The distinction matters primarily for insurance coverage and prescribing context. Mounjaro was approved by the FDA in May 2022 for type 2 diabetes management. Zepbound was approved in November 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition.
For a broader comparison of tirzepatide and semaglutide — the two dominant GLP-1 classes — see our semaglutide vs tirzepatide guide.
Side-by-Side Comparison
| Feature | Zepbound | Mounjaro |
|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide |
| FDA Approval | Obesity / Weight Management | Type 2 Diabetes |
| Approval Date | November 2023 | May 2022 |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15mg | 2.5, 5, 7.5, 10, 12.5, 15mg |
| Avg. Weight Loss | 20–22% (SURMOUNT-1) | 15–22% (SURPASS trials) |
| Dosing | Once weekly injection | Once weekly injection |
| Insurance Coverage | Obesity benefit (where exists) | Diabetes benefit |
| List Price/month | ~$1,059–$1,300 | ~$1,000–$1,300 |
| Compounded Version | Available (tirzepatide) | Available (tirzepatide) |
Cost and Insurance Differences
The list prices of Zepbound and Mounjaro are similar, but your out-of-pocket cost may differ significantly depending on your insurance coverage. This is where the approval indication matters most:
- Diabetes insurance plans: Mounjaro is covered when prescribed for T2D. If you have type 2 diabetes and a plan with diabetes coverage, Mounjaro may be $0–$25/month with savings programs or with insurance.
- Obesity benefit plans: Zepbound is covered under obesity management benefits — increasingly included in employer plans following the SELECT trial. Where this benefit exists, Zepbound copays can be as low as $25/month.
- No coverage: Both run $1,000–$1,300/month at list price. In this case, compounded tirzepatide through a program like Trimi reduces costs to $250–$450/month for the same active ingredient.
For a detailed cost analysis including all options, see our compounded tirzepatide cost guide.
Titration and Dosing — Identical Schedules
Whether you're prescribed Zepbound or Mounjaro, the dosing schedule is the same:
Tirzepatide Dose Escalation Schedule
The titration can be slowed at any step if GI side effects are problematic. Many patients find their optimal maintenance dose between 10mg and 15mg. For comprehensive side effect management, see our tirzepatide side effects guide.
Clinical Evidence: SURMOUNT vs SURPASS Trials
Zepbound's weight loss approval was supported by the SURMOUNT trials, which studied tirzepatide specifically in patients with obesity (without diabetes). SURMOUNT-1 showed 22.5% average weight loss at 15mg over 72 weeks. SURMOUNT-2 studied patients with obesity and type 2 diabetes, showing 15.7% weight loss.
Mounjaro's diabetes approval was based on the SURPASS trials, which included participants with type 2 diabetes. These trials showed significant HbA1c reduction alongside meaningful weight loss (up to 11.2kg on 15mg). The cardiovascular outcomes study SURPASS-CVOT added CV safety data.
Together, these trial programs make tirzepatide (in either brand form) the most evidence-backed GLP-1 medication for combined weight loss and metabolic health improvement available in 2026.
Choose Zepbound If:
- • Your primary goal is weight loss
- • You don't have type 2 diabetes
- • Your insurance has an obesity benefit
- • You want the specific obesity approval on your chart
Choose Mounjaro If:
- • You have type 2 diabetes
- • Your insurance covers diabetes drugs better
- • Your provider prefers the diabetes approval pathway
- • Zepbound is out of stock at your pharmacy
Frequently Asked Questions
Are Zepbound and Mounjaro the same drug?
Yes. Both Zepbound and Mounjaro contain the same active ingredient — tirzepatide — at the same doses. The difference is FDA approval: Mounjaro is approved for type 2 diabetes management, while Zepbound is approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions.
Can Mounjaro be used for weight loss?
Yes, Mounjaro can be and frequently is prescribed off-label for weight loss. Before Zepbound's approval in November 2023, Mounjaro was the only branded tirzepatide option. Many patients and providers continue to use Mounjaro off-label for obesity when Zepbound is unavailable or when a patient has diabetes.
Is Zepbound cheaper than Mounjaro?
The list prices are similar (~$1,000–$1,300/month), but Zepbound's pricing strategy has sometimes offered savings vials (single-dose vials at lower cost) compared to Mounjaro's auto-injector pens. Insurance coverage differs: Mounjaro may be covered by diabetes-focused plans while Zepbound falls under obesity/weight management benefits.
What doses do Zepbound and Mounjaro come in?
Both come in the same dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg weekly injections. The titration schedule is identical: start at 2.5mg, increase by 2.5mg every 4 weeks as tolerated, with a maintenance dose typically at 10mg, 12.5mg, or 15mg.
Which should I ask for — Zepbound or Mounjaro?
If your primary goal is weight loss and you don't have type 2 diabetes, ask for Zepbound — it has the specific obesity approval and may have different insurance coverage or savings programs. If you have type 2 diabetes, either works but Mounjaro may be better covered by diabetes-focused insurance plans.
Sources & References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM. 2022;387(3):205–216.
- Garvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." Lancet. 2023;402(10402):613–626.
- Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." NEJM. 2021;385(6):503–515.
- FDA. "FDA Approves New Medication for Chronic Weight Management." FDA.gov. November 8, 2023.